LON:HIK Hikma Pharmaceuticals (HIK) Share Price, News & Analysis GBX 2,088 +4.00 (+0.19%) As of 12:06 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainability About Hikma Pharmaceuticals Stock (LON:HIK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Hikma Pharmaceuticals alerts:Sign Up Key Stats Today's Range 2,080▼ 2,11250-Day Range 1,794▼ 2,091.9252-Week Range 1,750▼ 2,165Volume272,171 shsAverage Volume1.51 million shsMarket Capitalization£4.63 billionP/E Ratio3,212.31Dividend Yield2.97%Price TargetGBX 2,383.33Consensus RatingModerate Buy Company OverviewAt Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 670 (as of 31 December 2021) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 32 manufacturing facilities, 7 R&D centres and 8,700+ employees worldwide.Read More… Hikma Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks39th Percentile Overall ScoreHIK MarketRank™: Hikma Pharmaceuticals scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingHikma Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageHikma Pharmaceuticals has received no research coverage in the past 90 days.Read more about Hikma Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Hikma Pharmaceuticals is 3,212.31, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 111.77.Price to Earnings Ratio vs. SectorThe P/E ratio of Hikma Pharmaceuticals is 3,212.31, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 88.83.Price to Earnings Growth RatioHikma Pharmaceuticals has a PEG Ratio of 2.38. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHikma Pharmaceuticals has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for HIK. Dividend0.8 / 5Dividend StrengthWeak Dividend YieldHikma Pharmaceuticals pays a meaningful dividend of 3.25%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthHikma Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Hikma Pharmaceuticals is 9,538.46%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about Hikma Pharmaceuticals' dividend. Sustainability and ESG3.7 / 5Environmental Score-2.61 Short InterestThere is no current short interest data available for HIK. News and Social Media1.9 / 5News Sentiment0.43 News SentimentHikma Pharmaceuticals has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Hikma Pharmaceuticals this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Hikma Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Hikma Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders30.54% of the stock of Hikma Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.09% of the stock of Hikma Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Hikma Pharmaceuticals' insider trading history. Receive HIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address HIK Stock News HeadlinesEmergent BioSolutions gains exclusive commercial rights to KLOXXADOJanuary 14, 2025 | msn.comEBS obtains rights to Hikma's Kloxxado naloxone sprayJanuary 14, 2025 | msn.com24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast world of passive crypto income, where you set up a dependable income stream that works for you, whether you're at your computer or living your life.January 21, 2025 | Crypto Swap Profits (Ad)Hikma Pharma Inks Exclusive Commercial Deal With Emergent BioSolutions For KLOXXADO Nasal Spray 8 MgJanuary 14, 2025 | markets.businessinsider.comFDA Announcement: The First Generic GLP-1 Shot Has Just Been ApprovedJanuary 2, 2025 | msn.comFDA Approves First Generic Liraglutide Injection, Ushering in a New Era for Type 2 Diabetes TreatmentDecember 30, 2024 | msn.comIs Hikma Pharmaceuticals PLC (HIK.L) Among the U.K. Dividend Aristocrats for 2024?December 29, 2024 | msn.comFDA approves Hikma’s generic version of Novo’s diabetes drug VictozaDecember 25, 2024 | msn.comSee More Headlines HIK Stock Analysis - Frequently Asked Questions How have HIK shares performed this year? Hikma Pharmaceuticals' stock was trading at GBX 2,002.90 at the beginning of 2025. Since then, HIK stock has increased by 4.2% and is now trading at GBX 2,088. View the best growth stocks for 2025 here. How do I buy shares of Hikma Pharmaceuticals? Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Hikma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Hikma Pharmaceuticals investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW) and Athabasca Oil (ATH). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:HIK CUSIPN/A CIKN/A Webwww.hikma.com Phone+44-20-73992760FaxN/AEmployees9,100Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 2,383.33 High Stock Price TargetGBX 2,750 Low Stock Price TargetGBX 2,000 Potential Upside/Downside+14.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 0.65 Trailing P/E Ratio3,212.31 Forward P/E Ratio13.69 P/E Growth2.38Net Income£285 million Net Margins9.45% Pretax MarginN/A Return on Equity12.88% Return on Assets9.40% Debt Debt-to-Equity Ratio55.48 Current Ratio1.66 Quick Ratio1.27 Sales & Book Value Annual Sales£3.02 billion Price / Sales1.53 Cash FlowGBX 250.39 per share Price / Cash Flow8.34 Book ValueGBX 1,031 per share Price / Book2.03Miscellaneous Outstanding Shares221,880,000Free FloatN/AMarket Cap£4.63 billion OptionableNot Optionable Beta0.41 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (LON:HIK) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Hikma Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.